Clinical trials: Retinal Neovascularization
Macular Degeneration, Choroidal Neovascularization
Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD
Wet age-related macular degeneration (AMD) is caused by the formation and growth of abnormal blood vessels (angiogenesis) in the retina. The new blood vessels have fragile walls and can leak fluid into the retina.
- Trial name
- NCT00509548
- Testing
- TG100801
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- TargeGen
Neovascular Age-related Macular Degeneration
Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
The purpose of this study was to identify innovative early imaging parameters as predictors of the long-term clinical response to brolucizumab in terms of fluid resolution in patients with wet Age-related Macular Degeneration…
- Trial name
- IMAGINE (NCT04774926)
- Testing
- Brolucizumab
- Where
- 20 sites in Italy
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration
Genetic Study of Age-Related Macular Degeneration
This study will examine skin and blood cells for genetic changes related to the development of age-related macular degeneration, an eye disease that can significantly impair the ability to read, drive, and carry out daily…
- Trial name
- NCT00357578
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Carotid Stenosis
Chorioretinal Vascularization and Electrophysiological Changes After Carotid Revascularization
The aim of the study is to evaluate changes in retinal function by means of electro-functional examinations of the retina and to associate them with any changes in chorioretinal vascular density occurring in the ipsilateral eye…
- Trial name
- CAS-AOCT (NCT05835869)
- Testing
- Optical coherence tomography angiography and pattern electroretinogram
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
AMD, Wet AMD
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
The purpose of this study is to confirm the safety and establish the effectiveness of two doses from the IRay System for the treatment of wet AMD.
- Conditions
- AMD, Wet AMD, Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
- Trial name
- INTREPID (NCT01016873)
- Testing
- IRay
- Where
- 21 sites in Austria, Czechia and 3 more
- Volunteers
- 230 people
- Sponsor
- Oraya Therapeutics, Inc.
Macular Degeneration
Ranibizumab and Reduced Fluence PDT for AMD
Single agent anti-VEGF therapies such as ranibizumab have shown great promise and have set the standard for visual outcomes in treating wet macular degeneration.
- Trial name
- RAP (NCT00527475)
- Testing
- ranibizumab, verteporfin
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Texas Retina Associates
The Mechanism of Retinal Neovascularization of Diabetic, Retinopathy.
Clinical Research on Retinal Neovascularization of Diabetic Retinopathy
Retinal neovascularization of diabetic retinopathy might be associated with genetic risk factors and environmental risk factors.
- Trial name
- NCT01229540
- Testing
- genetic analyzer
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Age-related Macular Degeneration (ARMD)
Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment
The treatment landscape for neovascular AMD has evolved with various anti-VEGF agents since 2006. Ranibizumab initially led the way, but its limited efficacy in reducing retinal edema paved the way for aflibercept in 2011, which…
- Trial name
- NCT06683950
- Testing
- Aflibercept 8mg
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Kim's Eye Hospital
Neovascular Age-related Macular Degeneration
An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD
This study was designed to evaluate a variable dosing regimen with intravitreal ranibizumab for the treatment of patients with neovascular age-related macular degeneration (AMD) in the Prospective OCT Imaging of Patients with…
- Trial name
- NCT00373659
- Testing
- Ranibizumab (Lucentis)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Miami
Macular Degeneration, Maculopathy, Age-Related
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.
- Trial name
- NCT00058994
- Testing
- anecortave acetate
- Where
- United States
- Sponsor
- Alcon Research
Retinal Ischemia
Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease
The object of the study is to compare treatment of iris/angle neovascularization with panretinal photocoagulation (laser) to treatment with panretinal photocoagulation and an anti-angiogenic drug: ranibizumab.
- Trial name
- NCT00841373
- Testing
- Panretinal Photocoagulation, Panretinal Photocoagulation and intravitreal injection of ranibizumab
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Southern New England Retina Associates
Retinopathy of Prematurity
Safety and Efficacy of Propranolol Eye Drops in Treating Retinopathy of Premature
The aim of the present study is to evaluate the safety and efficacy of propranolol eye drops in preterm newborns with a precocious stage of retinopathy of prematurity (ROP).
- Trial name
- DROP-PROP (NCT02014454)
- Testing
- Propranolol eye drops
- Where
- 2 sites in Italy
- Volunteers
- 23 people
- Sponsor
- Meyer Children's Hospital IRCCS
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of KSI-301 administered at 12, 16 and 20 weeks intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in…
- Trial name
- DAZZLE (NCT04049266)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Czechia and 5 more
- Volunteers
- 559 people
- Sponsor
- Kodiak Sciences Inc
Age Related Macular Degeneration
Comparison Between Foresee Home and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)
The Foresee Home is used in the recent years to detect age-related macular degeneration (AMD) lesions. The device is capable of differentiation as to stages of AMD and early detection of changes including choroidal…
- Trial name
- NCT01073592
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Notal Vision Ltd.
Neovascular Age-Related Macular Degeneration
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration
The purpose of this study is to evaluate the safety and efficacy of single and repeated intravitreal injections of GB-102 in subjects with neovascular (wet) age-related macular degeneration.
- Trial name
- NCT03249740
- Testing
- GB-102, Aflibercept
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Graybug Vision
Choroidal Neovascularization, Macular Degeneration
Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration
Age-related macular degeneration (AMD) represents the most common cause of blindness in patients over the age of 60. The major cause of vision loss in this disease is due to the development of choroidal neovascular membrane…
- Trial name
- NCT00001615
- Testing
- Corticosteroid
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Eye Institute (NEI)
Age-related Macular Degeneration
Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. Patients will receive injections of ranibizumab.
- Trial name
- MAKO (NCT02727881)
- Testing
- Squalamine lactate ophthalmic solution, 0.2%, ranibizumab
- Where
- 118 sites in United States
- Volunteers
- 230 people
- Sponsor
- Ohr Pharmaceutical Inc.
Macular Degeneration, Wet Macular Degeneration
EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)
- Trial name
- EAGLE (NCT02689518)
- Testing
- Intravitreal aflibercept injection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Neovascular (Wet) Age-related Macular Degeneration
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
Researchers are looking for a better way to treat people who have neovascular (wet) age-related macular degeneration (nAMD or wet AMD).
- Trial name
- XPAND (NCT05473715)
- Testing
- Aflibercept(BAY86-5321, Eylea)
- Where
- 3 sites in Canada, United Kingdom
- Volunteers
- 3 people
- Sponsor
- Bayer
Pseudoxanthoma Elasticum
Evolution of Visual Impairment During Pseudoxanthoma Elasticum
Pseudoxanthoma elasticum is a disease whom frequency is estimated about 1/50000 to 1/100 000. There is a female preponderance with a sex-ratio of 2:1.
- Trial name
- NCT00555113
- Where
- France
- Volunteers
- 38 people
- Sponsor
- European Georges Pompidou Hospital